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Background: Haematological malignancies harbouring rearrangements of the
KMT2A gene represent a unique subtype of leukaemia, with biphenotypic clinical
manifestations, a rapid and aggressive onset, and a generally poor prognosis. Chromo-
somal translocations involving KMT2A often cause the formation of oncogenic fusion
genes, such as the most common translocation t(4;11)(q21;q23) producing the
KMT2A‐AFF1 chimera.
Aim: The aim of this study was to confirm and review the cytogenetic and molec-
ular features of the KMT2A‐rearranged RS4;11 cell line and put those in context with
other reports of cell lines also harbouring a t(4;11) rearrangement.
Methods and Results: The main chromosomal rearrangements t(4;11)(q21;q23) and
i(7q), described when the cell line was first established, were confirmed by fluores-
cence in situ hybridisation (FISH) and 24‐colour karyotyping by M‐FISH. Additional
cytogenetic abnormalities were investigated by further FISH experiments, including
the presence of trisomy 18 as a clonal abnormality and the discovery of one chromo-
some 8 being an i(8q), which indicates a duplication of the oncogene MYC. A homo-
zygous deletion of 9p21 containing the tumour‐suppressor genes CDKN2A and
CDKN2B was also revealed by FISH. The production of the fusion transcript
KMT2A‐AFF1 arising from the der(11)t(4;11) was confirmed by RT‐PCR, but sequenc-
ing of the amplified fragment revealed the presence of multiple isoforms. Two tran-
script variants, resulting from alternative splicing, were identified differing in one
glutamine residue in the translated protein.
Conclusion: As karyotype evolution is a common issue in cell lines, we highlight the
need to monitor cell lines in order to re‐confirm their characteristics over time. We
also reviewed the literature to provide a comparison of key features of several cell
lines harbouring a t(4;11). This would guide scientists in selecting the most suitable
research model for this particular type of KMT2A‐leukaemia.
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Leukaemia harbouring rearrangements of the KMT2A gene (formerly
known as MLL/mixed‐lineage leukaemia and also known as HRX or
TRX1) represent a unique subtype of acute leukaemia, characterised
by a rapid and aggressive onset with generally poor prognosis. KMT2A
rearrangements can give rise to different cellular phenotypes, with
affected cells showing an interesting lineage heterogeneity, hence
the designation of “mixed‐lineage”. Rearrangements involving KMT2A
are often found in de novo and DNA topoisomerase II inhibitor
therapy‐related myeloid and lymphoblastic acute leukaemias, with
varying incidence according to type and age.1 Overall, KMT2A rear-
rangements account for 10% of all acute leukaemias2 but are predom-
inantly found in infants between the age of 0 and 2 diagnosed with
acute lymphoblastic leukaemia (ALL; 70%‐80% of cases3,4) and in
therapy‐related acute myeloid leukaemia (AML) patients (up to 70%
of cases).5
Chromosomal translocations are common rearrangements in
KMT2A‐leukaemia,6 whereby the exchange of genetic material
between chromosomes brings the N‐terminus of KMT2A to fuse in‐
frame with the C‐terminus of a partner gene.7,8 The breakpoint region
of KMT2A covers approximately 8 kbp between exons 7 and 11.9
More than 90 partner genes for KMT2A have been identified, forming
the so‐called “MLL recombinome.” The most common translocation
partners are AFF1 (previously known as AF4) on 4q21, MLLT3 (AF9)
on 9q22, ELL on 19p13.1, MLLT1 (ENL) on 19p13.3, MLLT10 (AF10)
on 10p12, and MLLT4 (AF6) on 6q27, giving rise to t(4;11)(q21;q23),
t(9;11)(q22;q23), t(11;19)(q23;p13.1), t(11;19)(q23;p13.3), t(10;11)
(p12;q23), and t(6;11)(q27;q23), respectively.1 The in‐frame fusion of
KMT2A and a partner gene produces chimeric proteins with oncogenic
activity, which largely depends on the retained domains of KMT2A and
the characteristics of the fusion partner.10
The most common translocation in the MLL recombinome is the
t(4;11)(q21;q23), which produces the KMT2A‐AFF1 chimeric pro-
tein.1,11 The phenotype is mainly B‐ALL, with rare cases of AML.
These leukaemic cells possess a biphenotypic profile, as they co‐
express lymphoid and myeloid markers while maintaining a lympho-
blastic morphology, suggesting that the original malignant clone arises
from an early lymphoid/myeloid precursor.12
Leukaemia initiation by KMT2A rearrangements is thought to occur
via an improper expression and regulation of Hox genes.13 The KMT2A
protein is a homologue of the trithorax protein in Drosophila
melanogaster14 and functions as a transcriptional activator and regulator
of Hox genes during embryogenesis and haematopoiesis.15,16 AFF1 is a
nuclear protein acting as transcriptional regulator involved in
haematopoietic development of lymphoid precursors.17 The KMT2A‐
AFF1 fusions are capable of initiating andmaintaining an erroneous pro-
gramme of transcription with oncogenic consequences.18
It is a topic of debate whether KMT2A fusions alone are suffi-
ciently powerful to cause the disease, contradicting the “multi‐hit
model” that applies to most leukaemias.19 Supporting the prenatal ori-
gin of leukaemia, alterations of the KMT2A gene have been docu-
mented in utero.20 One of the most remarkable features of infantKMT2A‐leukaemia is the extraordinarily short latency and the limited
number of secondary somatic mutations,21 indicating that only a small
number of additional events may be necessary to initiate the malig-
nancy, if at all.22,23 Mutations in FLT3, KRAS, and NRAS have been pro-
posed as “second hits” drivers for leukaemogenesis of KMT2A‐
leukaemias.24,25
A reliable in vivo model faithfully mimicking the disease is still lack-
ing (reviewed in Ottersbach et al26). Interestingly, murine models so
far have achieved a transient production of KMT2A‐AFF1 proteins
but failed to express the phenotype observed in humans.27-29 Only
recently, the development of such models is becoming increasingly
closer to clinical phenotypes.30,31 Therefore, in vitro models have been
at the forefront of research into KMT2A‐leukaemia. Although at least
16 cell lines with the t(4;11) have been described, only four have been
appropriately authenticated.32,33 In this article, we focus on the re‐
visitation of the RS4;11 cell line, which was first established by Stong
et al34 from a 32‐year‐old female patient with relapsed ALL. The initial
karyotype described a t(4;11)(q21;q23) and the presence of an i(7q).
Our work focuses on the characterisation of cytogenetic and
molecular aspects of RS4;11 in comparison with previous work from
other groups. As karyotype evolution is common in extended cell cul-
tures,32 we highlight the need for a constant monitoring and validation
of cell lines to be used as a reliable research model. We also provide a
brief summary of characteristics of other KMT2A‐AFF1‐positive cell
lines and comment on their suitability to advance our understanding
of KMT2A‐driven leukaemogenesis.2 | MATERIALS AND METHODS
2.1 | Cell lines
The cell lines RS4;11 (ATCC CRL‐1873™) and Farage (ATCC CRL‐
2630™) were grown in RPMI 1640 (Gibco, Paisley, UK) supplemented
with 10% foetal bovine serum (FBS) (Gibco) and 1%
penicillin/streptomycin (100 UmL−1/μgmL−1) (Gibco), and incubated at
37°C in 5% CO2. Cells were passaged every 48 hours.2.2 | Fluorescence in situ hybridisation (FISH) and
M‐FISH
Metaphase chromosomes were obtained by adding colcemid (10 μg/
mL; Gibco, Paisley, UK) to cell cultures 1 hour before harvesting accord-
ing to well‐established methods.35 The commercially available DNA
probes XCAP 7 long, XCAP 7 short, XL 7q22/7q36, XL MLL Plus, XL
CDKN2A (Metasystems, Altlussheim, Germany), WCP18, WCP8,
WCPX (Cambio, Cambridge, UK), and a BAC‐derived DNA probe
RP11‐195E4 (BACPAC Resources Center, Oakland, US) labelled in
house were used for fluorescence in situ hybridisation (FISH) experi-
ments. The RP11‐195E4 spans the region 8q24.3 (141,431,223 to
141,608,396). Detailed information on all probes is reported inTable 1
. FISH was performed according to the manufacturer's instructions
(Metasystems) with minor modifications or according to existing
TABLE 1 Details of FISH probes used
Probe Name Ideogram Location Type Direct Labelling Manufacturer
XCAP 7 long 7q Partial paint Y Metasystems
XCAP 7 short 7p Partial paint Y Metasystems
XL7q22/7q36 7q22; 7q36 Multicolour single locus Y Metasystems
XL MLL plus 11q23.3 Dual‐colour single locus Y Metasystems
XL CDKN2A 9p21; 9p11‐q11 Dual‐colour single locus Y Metasystems
WCP18 18 Whole paint Y Cambio
WCP8 8 Whole paint Y Cambio
WCPX X Whole paint N Cambio
RP11‐195E4 8q24.3 Single colour N BACPAC resources center
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with a 22 × 22 coverslip. Sample and probe were denatured at 75°C
for 2 minutes, followed by hybridisation at 37°C overnight. Slides were
then washed in 2 × SSC (pH 7.0) for 5 minutes shaking, then transferred
to 0.4 × SSC (pH 7.0) at 72°C for 2minutes, followed by anotherwash in
2 × SSC/0.05% Tween20 for 30 minutes shaking, and a final wash in
1 × PBS for 5 minutes. Detection and signal amplification of biotin‐
labelled probes (WCPX and RP11‐195E4) were carried out using Cy3‐
conjugated avidin. Slides were counterstained with 4′,6‐diamidino‐2‐
phenylindole (DAPI, Vectashield, Vector Laboratories, Peterborough,
UK). Single or dual‐colour FISH images were viewed using Leica
DM4000 microscope and were captured using the integrated software
Leica Application Suite (LAS). M‐FISH was performed using M‐FISH
probe kit 24XCyte (Zeiss, Metasystems) according to the manufacturer
instructions. Images were acquired with Olympus BX60 microscope for
epifluorescence equipped with a JAI CVM4 camera (Leica Biosystems,
Wetzlar, Germany). In total, 25 karyotypes were analysed, using the
Cytovision software (Leica Biosystems, Wetzlar, Germany). Karyotypes
are described according to International System forHumanCytogenetic
Nomenclature (ISCN, 201636).2.3 | RT‐PCR and cloning of the KMT2A‐AFF1 fusion
Total RNA was extracted from cell cultures using TRIzol Reagent and
converted into cDNA using random hexamers and SuperScript III
reverse transcriptase, according to manufacturer's instructions
(Invitrogen, Paisley, UK). The KMT2A‐AFF1 fusion PCR fragment
was amplified according to the protocol of van Dongen et al37 using
the forward primer MLL‐C (5′‐AGGACCGCCAAGAAAAGA‐3′) and
the reverse primer AF4‐D (5′‐CGTTCCTTGCTGAGAATTTG‐3′) that
anneal to exon 7 on KMT2A and exon 7 on AFF1, respectively.
PCR products were analysed by 2% agarose gel electrophoresis,
purified using GeneJET PCR Purification Kit and cloned into pJET2.1vector (Fisher Scientific, UK). A number of clones containing the
insert were selected by colony PCR and then sequenced by
GENEWIZ UK Ltd.3 | RESULTS
3.1 | 24‐colour karyotyping by M‐FISH
All of the metaphases showed the presence of a derivative chromo-
some 11, carrying chromosome 4 material. In addition, the majority
of the cells (76%) also had a derivative chromosome 4 (containing
chromosome 11 material in 56% of the cells), and derivatives chromo-
somes 7 and 8 (Figure 1).
FISH using whole chromosome paints did not reveal any numerical
changes or major structural rearrangements in chromosomes 18 and X
in 20 metaphases analysed (Figure 2A,B). Analysis of 25 metaphases
by M‐FISH reported two cases of +18 but no anomalies for chromo-
some X. Other numerical changes detected by M‐FISH included +8,
−5, −7, −13, −16, and −22.3.2 | Confirmation of the major rearrangement
t(4;11)(q21;q23) involving KMT2A
The presence of the t(4;11)(q21;q23) was confirmed by M‐FISH
(Figure 1), from which both der(4) and der(11) could be identified.
The involvement of the KMT2A gene was further confirmed by FISH
using a dual‐colour break‐apart probe encompassing the KMT2A locus
at 11q23.3. One normal KMT2A allele could be seen as a yellow fusion
signal, whereas disruption of the KMT2A region would result in one
red and one green signal present on the der(11) and der(4), respec-
tively (Figure 3).
FIGURE 1 Representative karyotype of RS4;11 obtained by M‐FISH. In this metaphase, the karyotype was determined to be 46,XX,t(4;11)(q21;
q23),i(7)(q10),i(8)(q10). Arrows indicate the derivatives der(4) and der(11), i(7q) and i(8q)
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The presence of an i(7q) was detected by FISH using arm‐specific
chromosome paints for 7q (red) and 7p (green), and single locus probes
for bands 7q22 (red) and 7q36 (green). Arm‐specific probes showed
the complete coverage of one chromosome 7 in red, corresponding
to the long arm (Figure 2C). For single locus probes, this was con-
firmed by the presence of two additional signals for 7q22 and 7q36
on one chromosome 7 (Figure 2D).3.4 | Identification of an isochromosome 8q leading
to duplication of 8q24
M‐FISH (Figure 1) and FISH using WCP8 (Figure 2E) revealed two
copies of chromosome 8 different in size and centromere position.
FISH using a single locus DNA probe for 8q24.3 (RP11‐195E4) was
carried out to investigate a possible duplication of this locus. Signals
specific for this region were visible on opposite sides of the centro-
mere, suggesting the presence of an isochromosome 8q (Figure 2F).3.5 | Homozygous deletion of 9p21 detected by
FISH
The dual‐colour probe XL CDKN2A/2B highlighted the presence of
both chromosome 9 centromeres. However, lack of both signals for
9p21 revealed a homozygous deletion of that region (Figure 2G,H).3.6 | Confirmation of the expression of KMT2A‐AFF1
fusion by RT‐PCR
To confirm that the KMT2A‐AFF1 fusion mRNA is produced in RS4;11
cells, we amplified the cDNA fragment from exon 7 of KMT2A gene to
exon 7 of AFF1 gene, according to the protocol of van Dongen et al37
using cDNA generated from total RNA. Agarose gel electrophoresis
analysis demonstrates a successful amplification of the cDNA frag-
ment, which migration on the gel is consistent with the in silico calcu-
lated size for the amplified KMT2A‐AFF1 fusion of 502 BP (Figure 4A‐
C). Sequencing of the PCR product revealed a mixed sequence starting
after the last nucleotide of exon 9 of KMT2A gene (Figure 4D), indicat-
ing that it is spliced to the different 3′ splice sites. To confirm the pres-
ence of alternatively spliced isoforms and estimate the frequency of
the alternative splicing event, we cloned the PCR product into the
pJET2.1 vector and sequenced a number of clones. Analysis revealed
that 8 out of 11 sequenced clones match the sequence of a canonical
fusion transcript from the last nucleotide of exon 9 of KMT2A gene to
the first nucleotide of exon 7 of AFF1 gene (Figure 4E). Three out of
11 clones showed a deletion of the first three nucleotides (CAG) at
the beginning of exon 7 of AFF1 gene (Figure 4F). The deletion does
not cause changes in the reading frame, but results in the loss of a glu-
tamine (Q) residue in the translated sequence, producing two distinct
protein isoforms differing in one amino acid (Figure 4G). The genomic
sequence at the beginning of exon 7 of the AFF1 gene has a NAGNAG
motif that contains two 3′ splice sites in tandem. The NAGNAG is
often subjected to alternative splicing38,39; therefore, the detection
of noncanonical isoform is not very surprising. Nevertheless, it is
important to stress that both transcripts are the results of pre‐mRNA
splicing from exon 9 of KMT2A to exon 7 of AFF1.
FIGURE 2 Cytogenetic abnormalities
investigated by FISH in the RS4;11 cell line. A‐
B, Whole chromosome paints for
chromosomes X and 18 did not reveal any
numerical abnormalities. C‐D, An
isochromosome 7q was detected using an
arm‐specific probe (long arm in red and short
arm in green), panel C, and a single‐locus
probe for 7q22 (red) and 7q36 (green), panel
D. E, Whole chromosome paint for
chromosome 8 revealed a size difference
between chromosomes 8, with one copy
appearing metacentric. F, A duplication of the
8q24 region is visible on an isochromosome
8q, detected with the FISH probe RP11‐
195E4 specific for 8q24.3. G, Dual‐colour
FISH probe CDKN2A/2B XL showed a
homozygous deletion of the 9p21 locus by
observation of green centromeric signals only.
H, A representative metaphase from the
Farage cell line with two normal chromosomes
9 with the expected pattern for the CDK24A/
2B XL probe
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FIGURE 3 Dual‐colour FISH shows the KMT2A rearrangement in RS4;11. FISH using a break‐apart, dual‐colour probe mapping proximal (red)
and distal (green) to the KMT2A breakpoint region (A) shows the presence of green signals on the der(4), red signals on the der(11), and a
yellow fusion signal on the normal chromosome 11 on metaphase chromosomes (B) and in an interphase nucleus (C)
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The RS4;11 cell line was first established by Stong et al34 from the
leukaemic cells of a 32‐year‐old female patient with ALL at relapse.
Consistent with the original karyotype of the cell line, we identified
the characteristic translocation between chromosome 4 and 11,
namely t(4;11)(q21;q23), and the isochromosome of the long arm of
chromosome 7, namely i(7q). However, i(7q) was not present in the
initial karyotype of the patient at diagnosis, but arose as a secondary
abnormality in relapse, when RS4;11 was established.40,41 In light of
our results, the karyotype of RS4;11 is now revised as 47,XX,t(4;11)
(q21;q23),i(7)(q10),i(8)(q10),del(9p21)x2/idem,+8/idem,+18.
Additional numerical abnormalities have been previously described
in RS4;11, notably trisomy 8 and 18, and monosomy X.42,43 In our
study, although FISH using whole chromosome paints for chromo-
somes 8, 18, and X did not confirm these aneuploidies, two separate
clones with +8 and +18, respectively, were identified by M‐FISH.
Trisomy of chromosomes 8 and 18 can arise in extended cell cul-
tures and seems to confer a proliferative advantage by an increased
gene dosage effect.44,45 Trisomy 8 is present in the KMT2A‐
rearranged cell line MV‐4‐146 and in a number of myeloid leukaemia
cell lines such as K‐562,47 SKK‐1,48 and GDM‐1.49 Trisomy 18 is
more common in cell lines derived from solid tumours.44 In leukae-
mia patients, trisomy 8 is usually described in therapy‐related leukae-
mia or as a secondary clonal event,50,51 with a possible role in
disease progression rather than in primary leukaemogenesis.52
Although rare, trisomy 18 in leukaemia is mainly found in conjunc-
tion with other abnormalities, such as trisomy 12 or 16 in chronic
lymphocytic leukaemia (CLL), and is also regarded as an event of
clonal evolution.53,54We report the consistent presence of an i(8q) in RS4;11, which has
not been previously described. The formation of the i(8q) results in a
duplication of the proto‐oncogene c‐Myc mapping at 8q24.2, which
has been shown to provide selective growth advantage in vitro.55-57
In AML and ALL, i(8q) is considered to arise as a secondary clonal
abnormality contributing to disease progression and is often found in
conjunction with complex karyotypes.58,59
We confirmed the homozygous deletion at 9p21, a locus containing
CDKN2A andCDKN2B, coding for the tumour suppressors p16(INK4A)/
p14(ARF) and p15(INK4B), respectively. This was previously shown by
Southern blotting60 and by array‐comparative genomic hybridisation
(aCGH).43 As part of a large analysis of copy number abnormalities
(CNA) in more than 80 B‐ALL cell lines, Tomoyasu et al61 confirmed
the deletion of the 9p21 region in RS4;11 and also highlighted an overall
high frequency of this deletion in the cell lines analysed but a lower fre-
quency in KMT2A‐rearranged cell lines. Clinically, homozygous
del(9p21) is predominantly found in T‐ALL patients and particularly in
paediatric cases, in which the deletion confers poor prognosis.62,63
The del(9p21) in conjunction with t(4;11) or other KMT2A transloca-
tions are seen but at a lower frequency than in other cytogenetic sub-
groups such as t(1;19) and t(9;22)/BCR‐ABL, indicating that the
inactivation of CDKN2A/2B is not indispensable for the malignant
phenotype.64
At the molecular level, known breakpoints on KMT2A span the
region between exon 7 and exon 11, and in AFF1 the breakpoint
locates between exon 8 and exon 4.9,37 In RS4;11 the KMT2A
breakpoint has been shown to occur between exon 8 and 9 and
between exon 5 and exon 4 in AFF1.37,65 We confirmed the in‐frame
fusion of the two genes at these breakpoints generating the KMT2A‐
AFF1 transcript. Two distinct isoforms of the fusion are produced
FIGURE 4 The presence of the KMT2A‐AFF1 transcript in RS4;11 cells confirmed by RT‐PCR and sanger sequencing. A, Schematic
representation of the position of primers flanking the fusion fragment by the forward MLL‐C and reverse AF4‐D. B, The predicted sequence of
the RT‐PCR product amplified by the MLL‐C and AF4‐D primers (shown in red text and arrows) was estimated to be 502 BP in size. Accession
numbers in Ensembl for the KMT2A transcript: ENST00000534358.5; and for AFF1 transcript: ENST00000307808.10. C, Agarose gel
electrophoresis of the amplified fusion product (lane 2), alongside with the nontemplate control (lane 3). Molecular weight markers from the
Bioline HyperLadder I are shown in bp (lane 1). D, E, F, Representative sequencing chromatograms of the KMT2A‐AFF1 junction in the PCR
product (D) and in two distinct clones (E, F). The nucleotides of KMT2A exon 9 are highlighted in blue. The chromatogram was generated using
FinchTV software. G, Schematic representation of the KMT2A exon 9‐intron‐AFF1 exon 4 boundaries demonstrating how the alternative splicing
can generate a canonical KMT2A‐AFF1 transcript, corresponding to the chromatogram in (E) or the transcript containing the deletion of three
nucleotides at the beginning of AFF1 exon 4 that corresponds to the chromatogram in (F)
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estingly, up to eight different transcript variants are known to occur
in patients with t(4;11), although their significance has not been eluci-
dated.66-70 The NAGNAG motif, identified on exon 7 of the AFF1
gene, is estimated to be present in 30% of human genes, and it was
suggested that it may play a functional role in about 5% of the
genes.71 Analysis of an EST‐derived alternative splicing database
revealed that the NAGNAG motif is indeed subjected to alternative
splicing in about 50% cases,38 and moreover, the CAGCAG is a con-
sensus sequence.38,39 As the NAGNAG often undergoes alternative
splicing,38,39 the generation of noncanonical isoforms of the KMT2A‐
AFF1 transcripts is unsurprising.
The generation of the reciprocal fusion transcript AFF1‐KMT2A
from the der(4) was not investigated in our study, but its production
has been reported in RS4;11.72 The role of the AFF1‐KMT2A proteinin leukaemogenesis is still debated, as AFF1‐KMT2A transcripts are
only occasionally found in patients due to the fusion not consistently
occurring in‐frame.73 While some authors have shown that
AFF1‐KMT2A is required to achieve full malignant transformation,74,75
others did not find such association.72,76
Although at least 16 cell lines with the t(4;11) have been described,
only few have been appropriately authenticated (summarised inTable 2
).32,33 A similar cell line to RS4;11 is MV‐4‐11, harbouring a t(4;11)(q21;
q23) together with an additional copy of chromosome 8 and chromo-
some 19.84 MV‐4‐11 is morphologically macrophagocytic and was
established from a 10‐year‐old male patient with biphenotypic
myelomonocytic leukaemia.46 While RS4;11 serves as a model for
pre‐B lymphoblastic leukaemia, MV‐4‐11 caters well for studies on
myeloid and myelomonocytic cells.33 The SEM cell line also carries a
t(4;11), in conjunction with a del(7)(p14) and del(13)(q12), and was




















48,XY,t(4;11)(q21;q23),+8,+19 Y Y FLT3 ITD78;
WT TP5377
46
B‐1 ALL at relapse 14y/M Lymphoblast 45,XY,t(4;11)(q21;q23),t(1;8)(p36;q13),
t(1;10)(q11;p15),−4,+6,−9
Y N – der(4)
absent79
80
SEM B‐ALL at relapse 5y/F Lymphoblast 45,XX, t(4;11)(q21;q23),del (7)(p15),−13 Y Y FLT3 iAMP81 82
AN4;11 T‐ALL 8 m/M Lymphoblast 46,XY,t(4;11)(q21;q23) Y Y 83
Abbreviations: iAMP, intrachromosomal amplification; ITD, internal tandem duplication.
8 of 11 RAGUSA ET AL.established from a 5‐year‐old female ALL patient.82 AN4;11 was
derived from a 8‐month‐old diagnosed with T‐ALL with t(4;11) as the
sole abnormality reported.83 Finally, the B‐1 cell line was derived from
a relapsed ALL 14‐year‐old male with a more complex karyotype com-
pared with the other t(4;11) cell lines. B‐1 harbours a t(4;11) without a
der(4), as well as t(1;8)(p36;q13), t(1;10)(q11;p15), monosomies 4 and
9, and trisomy6.80 All cell lines generate theKMT2A‐AFF1 and the recip-
rocal AFF1‐KMT2A fusions,85 with the exception of the B‐1 cell line,
which only produce the KMT2A‐AFF1 from the der(11).79,80 In terms
of immunophenotypic profiling, they are all defined as biphenotypic
based on the co‐expression of lymphatic andmyeloid antigenic markers
CD10, CD19, CD13, CD34, and CD33.86
The MV‐4‐11, SEM, AN4;11, and B‐1 cell lines are particularly suit-
able for the study of childhood KMT2A leukaemia, as they were
established from paediatric patients, whereas RS4;11 can be consid-
ered a model to investigate adult relapsed forms. Studies on these cell
lines have also helped decipher key players in leukaemogenesis. For
instance, the absence of the der(4) in the B‐1 cell line, which is how-
ever present in MV‐4‐11, RS4;11, AN4;11, and SEM, suggests that it
is the der(11) to detain a pivotal role in the promotion and mainte-
nance of the malignancy.79,80 Differences in other molecular features,
such as mutations of known cancer‐related genes TP53 and FLT3, can
prove useful in investigating the role of point mutations in leukaemo-
genesis77,78,81 (Table 2).
We conclude that the RS4;11 cell line is a suitable in vitro model
for the study of leukaemia harbouring t(4;11), owing to the presence
and retention of its original cytogenetic abnormalities. At the molecu-
lar level, the production of the KMT2A‐AFF1 transcript is useful for
proteomic and pharmacological studies, and might help to shed some
light on the significance of transcript variants and alternative splicing.
As with other cell lines, the karyotype is subjected to evolution over
extended culturing, by the accumulation of secondary mutations and
rearrangements. Monitoring cell lines over time would provide further
information on clonal evolution and proliferative advantage of certain
subclones, such as the proportion of different clones within the popu-
lation, how they vary over time, and which abnormalities provide the
strongest growth advantage. While these changes may represent anobstacle in reproducibility and reliability of experiments, investigating
these changes could be used to understand tumour evolution in
patients.87,88
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